Effect of arundic acid on serum S-100β in ischemic stroke

Journal of the Neurological Sciences

Volumn 251, Issue 1-2, 2006, Pages 57-61

  Pettigrew, L Creed ^a   Kasner, Scott E ^b   Gorman, Mark ^c   Atkinson, Richard P ^d   Funakoshi, Yosuke ^e   Ishibashi, Hideyasu ^e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Mercy General Hospital   (United States)

^e ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Arundic acid; Astrocyte; Cerebral ischemia; S 100 protein

Indexed keywords

ARUNDIC ACID; BIOLOGICAL MARKER; PLACEBO; PROTEIN S100B;

ADULT; AGED; ARTICLE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN ISCHEMIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; OCTANOIC ACIDS; S100 PROTEINS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 33751220170     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.09.002     Document Type: Article

References (18)

1. Fagnart O.C., Sindic C.J., and Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34 7 (Jul 1988) 1387-1391
2. Aurell A., Rosengren L.E., Karlsson B., Olsson J.E., Zbornikova V., and Haglid K.G. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 22 10 (Oct 1991) 1254-1258
3. Büttner T., Weyers S., Postert T., Sprengelmeyer R., and Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 28 10 (Oct 1997) 1961-1965
4. Kim J.S., Yoon S.S., Kim Y.H., and Ryu J.S. Serial measurement of interleukin-6, transforming growth factor-b, and S-100 protein in patients with acute stroke. Stroke 27 9 (Sep 1996) 1553-1557
5. Persson L., Hårdemark H.G., Gustafsson J., Rundström G., Mendel-Hartvig I., Esscher T., et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18 5 (Sep-Oct 1987) 911-918
6. Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H., and Lamers K.J. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31 11 (Nov 2000) 2670-2677
7. Böttiger B.W., Möbes S., Glätzer R., Bauer H., Gries A., Bärtsch P., et al. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 103 22 (Jun 5 2001) 2694-2698
8. Martens P., Raabe A., and Johnsson P. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke 29 11 (Nov 1998) 2363-2366
9. Shimoda T., Tateishi N., Shintaku K., Yada N., Katagi J., Akiyama T., et al. ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Soc Neurosci Abstr 24 (1998) 384.13
10. A receptors on primary cultured astrocytes from the rat brain. Soc Neurosci Abstr 23 (1997) 845.7
11. A receptor disappearance in cultured astrocytes and ischemic brain. Soc Neurosci Abstr 25 (1999) 843.11
12. Shinagawa R., Tateishi N., Shimoda T., Shintaku K., Yada N., Honjo K., et al. ONO-2506 ameliorates neurodegeneration through inhibition of reduction of GLT-1 expression. Soc Neurosci Abstr 14 (1998) 384.14
13. Shinagawa R., Tateishi N., Shimoda T., Maekawa H., Yada N., Akiyama T., et al. Modulating effects of ONO-2506 on astrocytic activation in cultured astrocytes from rat cerebrum. Soc Neurosci Abstr 25 (1999) 843.10
14. Tateishi N., Mori T., Kagamiishi Y., Satoh S., Katsube N., Morikawa E., et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 22 (2002) 723-734
15. Pettigrew L.C., Kasner S.E., Albers G.W., Gorman M., Grotta J.C., Sherman D.G., et al. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 251 (2006) 50-56 10.1016/j.jns.2006.09.001 (this issue)
16. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 8 (Aug 2002) 495-505
17. Elting J.W., Sulter G.A., Kaste M., Lees K.R., Diener H.C., Hommel M., et al. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels. Stroke 33 12 (Dec 2002) 2813-2818
18. Wunderlich M.T., Ebert A.D., Kratz T., Goertler M., Jost S., and Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 30 6 (Jun 1999) 1190-1195